Ms Lin Bateson United Kingdom

Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK.

BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Organisation Type
BioPartner.co.uk

Mr Darius Bateson United Kingdom

Biopartner.co.uk, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK.

BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

Biopartner.co.uk has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Organisation Type
BioPartner.co.uk

Dr Simon Bryant United Kingdom





Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides services to approximately 300 customers throughout the world.


Website:
www.patheon.com
Organisation Type
Patheon (UK) Ltd
Business Development Manager 

Dr George Buckley United Kingdom

Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.

- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.

- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.

The identified protein domains are  used to quickly develop binding/activity assays for use in small molecule hit screening and/or to provide protein for structural studies. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging drug discovery programs. Domainex's approach enhances drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.

Doaminex also has an internal pipeline of novel cancer therapeutics.  The lead program is available for licensing and is a kinase inhibitor against the targets TBK1/IKKe.  Earlier programs in Domainex's pipeline include a number of epigenetic targets, such as the lysine methyltransferase, G9a.

Organisation Type
Domainex Ltd
Senior Business Development Manager 

Mr Simon Bury





Selcia Ltd is a leading provider of contract research services to the global life science industry.


Website:
www.selcia.com
Organisation Type
Selcia Limited
Business Development Director - Discovery